Sequenom Misses on the Top and Bottom Lines
Sequenom (NAS: SQNM) reported earnings on May 3. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Sequenom missed estimates on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP loss per share expanded.
Margins contracted across the board.
Sequenom logged revenue of $14.9 million. The nine analysts polled by S&P Capital IQ expected sales of $16.5 million on the same basis. GAAP reported sales were 10% higher than the prior-year quarter's $13.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.22. The 11 earnings estimates compiled by S&P Capital IQ averaged -$0.19 per share. GAAP EPS were -$0.22 for Q1 versus -$0.13 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 36.5%, 2,640 basis points worse than the prior-year quarter. Operating margin was -163.1%, 6,600 basis points worse than the prior-year quarter. Net margin was -163.9%, 7,010 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $19.1 million. On the bottom line, the average EPS estimate is -$0.21.
Next year's average estimate for revenue is $85.7 million. The average EPS estimate is -$0.86.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 658 members out of 714 rating the stock outperform, and 56 members rating it underperform. Among 154 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 138 give Sequenom a green thumbs-up, and 16 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sequenom is outperform, with an average price target of $6.73.
Over the decades, small-cap stocks like Sequenom have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Sequenom to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.